This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Karmanos Genitourinary Team Leader Contributes To Article On Prostate Cancer In New England Journal Of Medicine

DETROIT, April 8, 2013 /PRNewswire-USNewswire/ -- Ulka Vaishampayan, M.D., leader of the Genitourinary Oncology Multidisciplinary Team at the Barbara Ann Karmanos Cancer Center, has contributed to an article just published in The New England Journal of Medicine comparing two different therapeutic methods in the treatment of metastatic, hormone-sensitive prostate cancer that becomes unresponsive to traditional methods of therapy.


The article is titled, "intermittent versus Continuous Androgen Deprivation in Hormone Sensitive Metastatic Prostate Cancer Patients: Results of S9346 (INT-0162) an International Phase III Trial." Fellow authors come from across America and internationally. The lead author, Maha Hussain, M.D., is from the University of Michigan.

The Phase III trial began in 1995 and was completed in 2008 though patient follow-up has continued since completion. A total of 3,040 patients were accrued for the trial and 1,535 patients were randomized into receiving either complete androgen-deprivation therapy or intermittent androgen-deprivation therapy. Karmanos researchers recruited 112 patients onto the clinical trial, which represents one of the largest single institution accruals, according to Dr. Vaishampayan.

The objective of the trial was to determine whether survival using intermittent androgen deprivation would provide better survival rates and quality of life for men compared to continuous androgen deprivation.  Prostate cancer is an androgen-dependent disease and continuous androgen deprivation has been the standard therapy for metastatic (cancer that has spread), hormone-sensitive disease. Androgen is a male sex hormone, which includes testosterone.

Researchers ultimately determined that intermittent androgen deprivation does not achieve comparable survival rates compared to complete androgen deprivation therapy, though it does provide small improvements in quality of life (i.e. emotional well-being and sexual function) for men with prostate cancer, but only in the first three months of receiving the intermittent therapy.

Previous studies showed that intermittent androgen deprivation had prolonged the time between disease diagnosis and development of 'castrate-resistant' disease.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,803.84 -9.55 -0.05%
S&P 500 2,092.34 +3.47 0.17%
NASDAQ 5,131.8050 +15.6620 0.31%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs